This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
In Truth Social, Trump also claimed that Xi agreed on rebranding artificial intelligence to "super intelligence", saying "Like almost everyone else, he seemed to like calling the poorly and inaccurately named Artificial Intelligence to a far more accurate and important name, SUPER INTELLIGENCE" and that "That would be ‘SUPER!’ Everyone last night agreed, also." In response, the spokesperson of the Ministry of Foreign Affairs of China said that China respects the US's use of the term "super intelligence". Russian President Vladimir Putin commented on the visit, saying that Russia welcomes dialogue between the United States and China, and that whatever results the United States and China achieve will affect the entire world economy. After Xi left the US, President Trump called Japanese Prime Minister Sanae Takaichi. Trump explained to Takaichi the content of his talks with Xi Jinping during the meeting. The two exchanged views on China-related issues. Takaichi said that she and Trump maintained communication before and after Xi's visit, showing the close relationship between the US and Japan.
== Objectives == To promote the advancement of education and research into epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. To arrange conferences on aspects of wound management throughout Europe. To arrange multi-centre, multi-disciplinary training courses on topical aspects of wound healing. To create a forum for networking for all individuals and organisations interested in wound management
The Revolt, written by Menachem Begin before he became Prime Minister, tells the story of the Lehi (referred to by their translated name's acronym, F.F.I. "Freedom Fighters of Israel" in early English editions) and Begin's own Irgun fighters during the Jewish insurgency in Palestine. The Revolt influenced groups from a wide variety of ideologies. Some of these groups began to use suicide attacks in the 1990s. The book was allegedly found Osama bin Laden's al-Qaeda organization. Begin praised his militants' willingness to die, "These two wonderful young men greeted the sentence with the singing of Hatikvah". The "two wonderful young men" were the two who blew themselves up in 1947, he described their deaths, "even before they put on their red uniforms. They too held their heads high when they faced their judges… But they did not reach the gallows. They too sang on the threshold of death — a song of faith in God: 'Lord of the world who reigned before creation'. But their song ended with a great explosion which shattered the silence of the prison in occupied Jerusalem". In 1977 the author became prime minister, after previously being in opposition. Historical militants featured prominently in his political speeches. He praised the actions of his militants during the insurgency in Palestine in the 1940s, including the leader of the cell who bombed the King David Hotel (killing 91 people and 1 terrorist). His favourites were, again, the two young militants who blew themselves up in Jerusalem prison in 1947.
Prolific in film since 1964, Freeman is known for his roles in genres ranging from dramas, historical epics, thrillers, action adventure, science fiction, and comedies. His most acclaimed and highest-grossing films, according to the review aggregate site Rotten Tomatoes, include the following:
== Pharmacological effects == Calendula officinalis oil is still used medicinally as an anti-inflammatory and a remedy for healing wounds. Calendula ointments are skin products available for use on minor cuts, burns, and skin irritation; though evidence of their effectiveness is weak. Plant pharmacological studies have suggested that Calendula extracts have antiviral, antigenotoxic, and anti-inflammatory properties in vitro. In herbalism, Calendula in suspension or in tincture is used topically for treating acne, reducing inflammation, controlling bleeding, and soothing irritated tissue. Limited evidence indicates Calendula cream or ointment is effective in treating radiation dermatitis. Topical application of C. officinalis ointment has helped to prevent dermatitis and pain; thus reducing the incidence rate of skipped radiation treatments in randomized trials. Calendula has been used traditionally for abdominal cramps and constipation. In experiments with rabbit jejunum, the aqueous-ethanol extract of C. officinalis flowers was shown to have both spasmolytic and spasmogenic effects, thus providing a scientific rationale for this traditional use. An aqueous extract of C. officinalis obtained by a novel extraction method has demonstrated antitumor (cytotoxic) activity and immunomodulatory properties (lymphocyte activation) in vitro, as well as antitumor activity in mice. Calendula plants are known to cause allergic reactions in susceptible individuals, and should be avoided during pregnancy.
Sources: en.wikipedia.org
Blood fatty acids adopt distinct forms in different stages in the blood circulation. They are taken in through the intestine in chylomicrons, but also exist in very low density lipoproteins (VLDL) and low density lipoproteins (LDL) after processing in the liver. In addition, when released from adipocytes, fatty acids exist in the blood as free fatty acids. It is proposed that the blend of fatty acids exuded by mammalian skin, together with lactic acid and pyruvic acid, is distinctive and enables animals with a keen sense of smell to differentiate individuals.
Changes to the curriculum of American history during the 2010s, especially in left-leaning states, have led to large numbers young Americans having a low opinion of their country and their historical figures. On the other hand, the decline of belief in American exceptionalism is a long-term trend, not unique to this cohort.
Necrophagous flies have several traits and adaptations that facilitate their feeding behavior. For example, blow flies and flesh flies have a well-developed sense of smell and are highly mobile. This enables them to rapidly detect and locate carrion. Also, flesh flies and some blow flies lay larvae instead of eggs. This gives these flies a competitive advantage over other slower-developing, egg-laying species. In addition, blow flies, flesh flies, muscid flies and black soldier flies have many defenses against the pathogens and toxins found in carrion. These include a protective lining in their midgut, antibiotic-producing microbiota species, and a large number of pattern recognition receptors, lysozymes, antimicrobial peptides and detoxification enzymes. The diversity and abundance of necrophagous fly species vary geographically and seasonally. For example, Chrysomya species are present in subtropical regions of the USA but are rare in most of Canada. This geographic variation is attributable to factors such as soil type and meteorological conditions, and the effects these have on carrion decomposition. Whether urbanization affects fly species richness is open to dispute. Seasonally, many necrophagous fly species are observed in higher abundance in summer, but Thyreophora cynophila is more active in winter. Flies play a critical role in forensic science as they are often the first insects to discover and colonize human remains. Blow flies can arrive within minutes and begin laying eggs in the nose, mouth and other openings.
This supplementation can offer a protective boost, enhancing the infant's ability to fend off infections and other health threats during the critical years when their immune system is still developing. The importance of this period underscores the need for targeted nutritional interventions to support overall immune health in young children.
== Function == CENPA is a protein which epigenetically defines the position of the centromere on each chromosome, determining the position of kinetochore assembly and the final site of sister chromatid cohesion during mitosis. This proteins is frequently accompanied by "centrochromatin"-associated changes to canonical histones and is constitutively present in centromeres. The CENPA protein is a histone H3 variant which replaces one or both canonical H3 histones in a subset of nucleosomes within centromeric chromatin. CENPA has the greatest sequence divergence of the histone H3 variants, with just 48% similarity to canonical histone H3, and has a highly diverged N-terminal tail that lacks many well characterised histone modification sites including H3K4, H3K9 and H3K27. Unusually for a histone, CENPA nucleosomes are not loaded together with DNA replication and are loaded at different cell cycle stages in different organisms: G1 phase in human, M phase in drosophila, G2 in S. pombe. To orchestrate this specialised loading there are CENPA-specific histone chaperones: HJURP in human, CAL1 in drosophila, nefr-1 in C. elegans and Scm3 in S. pombe. In most eukaryotes CENPA is loaded into large domains of highly repetitive satellite DNA. The position of CENPA within satellite DNA are heritable at the protein level through a purely epigenetic mechanism. This means that the position of CENPA protein binding to the genome is copied upon cell division to the two daughter cells independent of the underlying DNA sequence.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.